ERBB2 and breast carcinoma: The large phase III GeparSepto trial compared neoadjuvant paclitaxel 80 mg/m2 qw vs nab-paclitaxel 125 mg/m2 (150 mg/m2 before amendment) qw followed by epirubicin and cyclophosphamide (EC) for early-stage breast cancer, with trastuzumab plus pertuzumab added for HER2-positive cancers [11].